Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma
Titel:
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma
Auteur:
Moskowitz, C.H. Hamlin, P.A. Gabrilove, J. Bertino, J.R. Portlock, C.S. Straus, D.J. Gencarelli, A.N. Nimer, S.D. Zelenetz, A.D.